Skip to main content
IDEAYA Biosciences, Inc. logo

IDEAYA Biosciences, Inc. — Investor Relations & Filings

Ticker · IDYA ISIN · US45166A1025 LEI · 549300ULW08F62IJML11 US Manufacturing
Open in API
Filings indexed 467 across all filing types
Latest filing 2026-06-08 Capital/Financing Update
Country US United States of America
Listing US IDYA

About IDEAYA Biosciences, Inc.

https://www.ideayabio.com/

IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 90% confidence The document is a preliminary prospectus supplement on Form 424B5 dated June 8, 2026, for a $300 million offering of common stock and pre-funded warrants by IDEAYA Biosciences. It is clearly an offering document reflecting a financing activity rather than an annual report, earnings release, or other filings. Under the provided definitions, this falls squarely under “Capital/Financing Update (CAP)” as it details a new share issuance and financing terms.
2026-06-08 English
8-K
Regulatory Filings Classification · 85% confidence The document is a Form 8-K “Current Report” filed with the SEC under the Exchange Act. It discloses an “Other Events” item (Item 8.01) announcing a clinical collaboration. It is not an earnings release, financial report, or specific corporate action like a merger or dividend. Therefore, it falls under general regulatory filings (RNS) as a miscellaneous SEC filing.
2026-06-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, containing Regulation FD disclosure and other event updates. Form 8-K filings are standard regulatory filings disclosing material corporate events and are not the actual investor presentation or standalone financial report. This fits the definition of a general regulatory announcement (RNS).
2026-06-01 English
S-3ASR - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Regulatory Filings Classification · 78% confidence The document is a Form S-3 registration statement/prospectus filed with the U.S. SEC under the Securities Act of 1933, outlining a shelf registration for potential future offerings of common stock, preferred stock, debt securities, warrants, and units. It is not an earnings release, annual report, management discussion, dividend notice, or M&A filing; it is a regulatory filing related to securities registration. Therefore, it falls under the catch-all “Regulatory Filings” category (RNS).
2026-05-05 English
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Earnings Release Classification · 90% confidence The document is a Form 8-K current report under Item 2.02 “Results of Operations and Financial Condition,” disclosing the company’s first quarter financial results via a press release (Exhibit 99.1). This corresponds to an earnings release rather than an annual or interim report, management discussion, or other filing type. Q1 2026
2026-05-05 English
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events or updates by a company. The content focuses on a clinical update regarding a Phase 2/3 trial's topline results and plans for an NDA submission. It does not contain comprehensive financial statements or detailed financial analysis. The document is not an earnings release, annual report, or interim report. It is an announcement of clinical trial results and future regulatory plans, typical of a current report (8-K) filing. Given the nature of the content and the form type, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.